Axsome Therapeutics is in focus ahead of a key FDA decision on its Alzheimer's agitation drug AXS-05, with a verdict due April 30. The treatment targets a large patient population, and positive approval could be a major catalyst, helping drive the stocks recent 15% monthly gain.